Bharat Parenterals Ltd (BPLPHARMA) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Innoxcel Lifesciences began its first US commercial supply in October, marking its transition from a development-focused entity to a recurring revenue CMO.
- The company raised INR 139 crores through a preferential issue to fund expansion in its subsidiaries, with CRISIL monitoring the capital's deployment.
- Management reaffirmed full-year FY27 guidance, expecting the standalone business to deliver on its INR 117 crore order book to meet growth targets in H2.
Performance Overview
- Delivered a strong quarter with consolidated revenue growing 110% YoY and 45% sequentially, signaling a commercial inflection point.
- EBITDA margin expanded significantly by over 800 basis points in a single quarter, reaching 17.3% from 9.1% in Q1 FY27.
- The company achieved a profit after tax of INR 11.8 crores, a sharp turnaround from a loss of INR 8.6 crores in the same quarter last year and a loss of INR 3.6 crores last quarter.
- Strategic shift towards higher-margin businesses is yielding results, with Innoxel and Varenyam Healthcare now contributing 45% of total revenue.
- Innoxcel Lifesciences became the group's largest EBITDA contributor, generating over 50% of the total EBITDA, highlighting its growing importance.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.